Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19. | Lancet Respir Med;9(11): 1207-1209, 2021 11. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19.

Richardson, Christopher D.

Richardson CD; Department of Microbiology & Immunology/Pediatrics, Canadian Center of Vaccinology, Dalhousie University, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: chris.richardson@dal.ca.

Lancet Respir Med ; 9(11): 1207-1209, 2021 11.

Article in English | MEDLINE | ID: covidwho-1356513

Subject(s)

BNT162 Vaccine; COVID-19; Immunogenicity, Vaccine; BNT162 Vaccine/immunology; COVID-19/prevention & control; Humans; Vaccination

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 / BNT162 Vaccine Topics: Vaccines Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 / BNT162 Vaccine Topics: Vaccines Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article